Grant✓ Small businesses may apply
Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
National Institutes of Health
- Opportunity #
- PAR-25-040
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.242
- Status
- posted
- Posted
- Nov 18, 2024
- Closes
- Sep 7, 2026
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Public housing authorities/Indian housing authorities
- •County governments
- •State governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •For profit organizations other than small businesses
- •Independent school districts
- •Small businesses
- •Special district governments
- •City or township governments
- •Public and State controlled institutions of higher education
- •Native American tribal governments (Federally recognized)
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Private institutions of higher education
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts.
Contact
National Institutes of Health · grantsinfo@nih.gov